KNSA news & sentiment — Kiniksa Pharmaceuticals International, plc

MAY 3·MinichartLow

Kiniksa Pharmaceuticals International plc Files 8-K: Announces Consulting Agreement Details and Company Information (April 30, 2026)

Kiniksa Pharmaceuticals International plc announced the resignation of its Chief Strategy Officer, Eben Tessari, effective May 15, 2026. Mr. Tessari will transition to a consulting and advisory role for the company's Science and Research Committee, assuaging concerns about abrupt leadership changes. The company emphasized that his departure was voluntary and not due to any disagreement with company operations or policies.

APR 29·Stock Titan

Kiniksa (KNSA) director Quart exercises options, sells 13,099 shares under 10b5-1 plan

Kiniksa Pharmaceuticals International, plc director Barry D. Quart exercised options to acquire 13,099 Class A Ordinary Shares at $14.33 per share and subsequently sold them at a weighted average price of $50.10. This transaction was conducted under a pre-arranged Rule 10b5-1 plan, indicating a pre-planned liquidity event. Following these actions, Quart directly holds 12,546 shares and retains 13,237 fully vested share options.

APR 28·Seeking Alpha

Kiniksa posts Q1 beat thanks to Regeneron drug (KNSA:NASDAQ)

Kiniksa Pharmaceuticals (KNSA) stock reached a 52-week high after reporting better-than-expected Q1 2026 earnings and raising its full-year outlook. The positive performance is attributed to strong sales of Arcalyst, its heart disease therapy, which is licensed from Regeneron (REGN).

$KNSA

Kiniksa Pharmaceuticals International plc Files 8-K: Announces Consulting Agreement Details and Company Information (April 30, 2026)

Kiniksa (KNSA) director Quart exercises options, sells 13,099 shares under 10b5-1 plan

Kiniksa posts Q1 beat thanks to Regeneron drug (KNSA:NASDAQ)

News on $KNSA